家畜用医薬品市場：製品タイプ、疾患タイプ、動物タイプ、製剤、投与経路、エンドユーザー別-2025-2030年世界予測

家畜用医薬品市場は、2024年には195億6,000万米ドルとなり、2025年には205億6,000万米ドル、CAGR 5.27%で成長し、2030年には266億3,000万米ドルに達すると予測されています。

家畜医療セクターは、技術革新、研究、テクノロジーが治療プロトコルを再定義し、生産性を向上させるために融合するダイナミックな環境という重要な岐路に立っています。近年、この業界は、進化する消費者の要求、規制の圧力、画期的な科学の進歩によって大きな変化を経験しています。本レポートでは市場を深く掘り下げ、現在の動向と実用的な洞察を融合させた広範な概観を提供します。

世界人口が増加し、持続可能なタンパク質源の必要性が高まる中、家畜のケアは製薬会社、獣医専門家、農業利害関係者にとって重要な焦点となっています。この包括的な分析の範囲には、製品開発と応用に影響を与える様々な要因のレビューが含まれます。科学的な革新と実用的な現場での応用の融合を探求し、有益かつ将来を見据えた統合的な物語を構築しています。

詳細な市場概要の提示に加え、本レポートはこの分野における変革的な変化にも焦点を当てています。こうした変化により、成長機会の特定、投資の最適化、そして最終的には研究と技術の進歩に歩調を合わせて動物の健康管理を継続的に進化させるための、より科学的でデータ主導型のアプローチが促進されています。すべての論点は、あらゆるレベルの意思決定者に力を与えるために、確かなデータに裏打ちされ、実世界での応用に基づいています。

家畜用医薬品市場の変革

近年、家畜医療は、技術統合、データ解析の強化、精密獣医療への重点化の結果、極めて重要な変貌を遂げています。高度な診断ツールや革新的な治療方法の導入により、従来のアプローチは再定義され、獣医の専門家は疾病の発生を緩和し、家畜の生産性を最適化するために積極的な姿勢をとることができるようになりました。

最近では、デジタル技術によって膨大なデータセットの収集と分析が容易になり、疾病予測の改善と薬剤処方の最適化が実現しました。顕著な変化は、従来の方法論から、疾病予防と牛群管理全体を考慮したより総合的なアプローチへの移行です。この進化するパラダイムは、食糧安全保障の強化と持続可能な農業慣行の実現に向けた世界の推進力と一致しています。

さらに、規制枠組みの調査と市場力学の進化により、業界各社はかつてないほど研究開発への投資に舵を切っています。精密投与や遺伝子組換えワクチンといった最先端のソリューションの採用は、治療効果を向上させるだけでなく、薬剤耐性のリスクも低減させています。こうした変革的なシフトは、革新的な戦略と適応力のあるビジネスモデルの重要性を浮き彫りにしており、刻々と変化する市場環境の中で、このセクターが機敏に対応し続けることを保証しています。

進化する市場における主要セグメンテーションの洞察

市場セグメンテーションを十分に理解することで、畜産医療を多面的に捉えることができます。これらの洞察は、製品タイプ、疾患タイプ、動物タイプ、製剤、投与経路、エンドユーザーによって定義される主要セグメントから浮かび上がってくる。製品タイプの観点からは、抗炎症剤、抗生物質、抗寄生虫剤、飼料添加物、ホルモン剤、ワクチンが業界を牽引していることが市場調査で明らかになりました。各カテゴリーを深く掘り下げると、抗生物質はセファロスポリン、ペニシリン、テトラサイクリンに基づいて精査され、抗寄生虫剤は外部寄生虫駆除剤と内部寄生虫駆除剤にまたがってさらに分析されています。同様に、飼料添加物はプレバイオティクスとプロバイオティクスに、ホルモンは成長ホルモンと生殖ホルモンに、ワクチンは不活化ワクチン、弱毒生ワクチン、サブユニットワクチンに分類されます。

さらに、疾病タイプに基づく区分では、感染症、代謝性疾患、栄養欠乏性疾患、寄生虫性疾患、生殖器疾患を検証しています。各疾患カテゴリーには、治療ソリューションのさらなるイノベーションを推進する独自の課題と成長機会が存在します。動物タイプ別では、水産養殖、ウシ、ヤギ、家禽、ヒツジ、ブタが分析対象となり、多様な飼育方法が製品需要や治療アプローチにどのような影響を及ぼすかが強調されています。

製剤別では、カプセル、ゲル、液体、粉末、錠剤に分類され、投与経路では、吸入、注射、経口、外用にまたがる同様の反射分割が観察されます。注目すべきは、注射剤では筋肉内投与と静脈内投与が綿密に調べられ、経口剤では液剤と錠剤が区別され、局所投与ではクリームとパッチが分析されていることです。最後に、エンドユーザーに基づくセグメンテーションでは、畜産農家、動物診療所、動物病院のニーズに焦点を当てています。この詳細なセグメンテーションの枠組みにより、きめ細かな視野が確保され、利害関係者は特定の市場ニッチとターゲットセグメントを正確かつ戦略的に明確に特定することができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 動物福祉を確保し、病気の蔓延を最小限に抑えるための政府の規制と取り組みの強化
    • 畜産農家の間で予防ヘルスケア対策のメリットに対する意識が高まっている
    • 家畜疾病の蔓延により動物用医薬品への投資が増加
  • 抑制要因
    • 限られた調査資金とイノベーションが次世代の家畜医薬品の開発を遅らせている
  • 機会
    • 規制の変更に対応した畜産における抗生物質代替品の拡大
    • 新興家畜疾病に対する画期的なワクチンを開発するためのバイオテクノロジー企業との協力
  • 課題
    • 畜産業界における疾病発生のリスクとバイオセキュリティ
• 市場セグメンテーション分析
  • 製品タイプ：家畜集団における細菌感染の予防と管理における抗生物質の重要性の高まり
  • エンドユーザー：家畜の精密医療の実施における獣医病院の役割の高まり
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 家畜用医薬品市場：製品タイプ別

• 抗炎症剤
• 抗生物質
  • セファロスポリン
  • ペニシリン
  • テトラサイクリン
• 抗寄生虫剤
  • 外部寄生虫駆除剤
  • 内部寄生虫駆除剤
• 飼料添加物
  • プレバイオティクス
  • プロバイオティクス
• ホルモン
  • 成長ホルモン
  • 生殖ホルモン
• ワクチン
  • 不活化ワクチン
  • 生弱毒化ワクチン
  • サブユニットワクチン

第7章 家畜用医薬品市場：疾患タイプ別

• 感染症
• 代謝性疾患
• 栄養欠乏症
• 寄生虫病
• 生殖疾患

第8章 家畜用医薬品市場動物の種類別

• 養殖業
• 牛
• ヤギ
• 家禽
• 羊
• 豚

第9章 家畜用医薬品市場処方別

• カプセル
• ゲル
• 液体
• 粉末
• タブレット

第10章 家畜用医薬品市場：投与経路別

• 吸入
• 注射剤
  • 筋肉内
  • 静脈内
• オーラル
  • 液体
  • タブレット
• トピック
  • クリーム
  • パッチ

第11章 家畜用医薬品市場：エンドユーザー別

• 畜産農家
• 獣医クリニック
• 動物病院

第12章 南北アメリカの家畜用医薬品市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の家畜用医薬品市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの家畜用医薬品市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Anicon Labor GmbH by SAN Group GmbH
• AniCura Group by Mars Petcare
• Biogenesis Bago SA
• Boehringer Ingelheim International GmbH
• Calier Laboratories S.A.
• Ceva Sante Animale
• Dechra Pharmaceuticals PLC
• Elanco Animal Health Inc.
• HESTER BIOSCIENCES LIMITED
• HIPRA S.A.
• Indian Immunologicals Ltd.
• Koninklijke DSM N.V.
• Merck KGaA
• Neogen Corporation
• Norbrook Laboratories Ltd.
• Parnell Pharmaceuticals Holdings Ltd.
• Phibro Animal Health Corporation
• Vetoquinol S.A.
• Vetpharma Animal Health S.L.
• Virbac SA
• Zoetis Inc.

LIST OF FIGURES

• FIGURE 1. LIVESTOCK MEDICINE MARKET MULTI-CURRENCY
• FIGURE 2. LIVESTOCK MEDICINE MARKET MULTI-LANGUAGE
• FIGURE 3. LIVESTOCK MEDICINE MARKET RESEARCH PROCESS
• FIGURE 4. LIVESTOCK MEDICINE MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 23. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. LIVESTOCK MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 29. LIVESTOCK MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. LIVESTOCK MEDICINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. LIVESTOCK MEDICINE MARKET DYNAMICS
• TABLE 7. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ENDOPARASITICIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PREBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GROWTH HORMONES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE HORMONES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY NUTRITIONAL DEFICIENCY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CATTLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GOATS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POULTRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SHEEP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SWINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 55. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 56. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 57. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 58. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 59. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 60. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 61. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 62. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PATCHES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 63. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 64. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 65. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVESTOCK FARMERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 66. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 67. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 68. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 69. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 70. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 71. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 72. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 73. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 74. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 75. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 76. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 77. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 79. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 80. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 81. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 82. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 84. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 85. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 86. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 87. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 88. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 89. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 90. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 91. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 92. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 94. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 95. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 96. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 97. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 98. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 99. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 100. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 101. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 102. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 103. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 104. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 105. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 106. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 108. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 109. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 110. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 111. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 112. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 113. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 114. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 115. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 116. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 117. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 118. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 119. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 120. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 122. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 123. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 124. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 125. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 126. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 127. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 128. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 129. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 130. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 131. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 132. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 133. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 134. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 136. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 137. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 138. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 139. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 141. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 142. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 143. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 144. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 145. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 147. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 148. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 150. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 151. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 152. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 153. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 154. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 155. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 156. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 157. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 158. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 159. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 160. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 161. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 162. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 163. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 165. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 166. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 167. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 168. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 169. AUSTRALIA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 170. AUSTRALIA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 171. AUSTRALIA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 172. AUSTRALIA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 173. AUSTRALIA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 174. AUSTRALIA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 175. AUSTRALIA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 176. AUSTRALIA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 177. AUSTRALIA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 178. AUSTRALIA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. AUSTRALIA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 180. AUSTRALIA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 181. AUSTRALIA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 182. AUSTRALIA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 183. CHINA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 184. CHINA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 185. CHINA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 186. CHINA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 187. CHINA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 188. CHINA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 189. CHINA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 190. CHINA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 191. CHINA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 192. CHINA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 193. CHINA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 194. CHINA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 195. CHINA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 196. CHINA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 197. INDIA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 198. INDIA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 199. INDIA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 200. INDIA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 201. INDIA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 202. INDIA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 203. INDIA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 204. INDIA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 205. INDIA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 206. INDIA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 207. INDIA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 208. INDIA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 209. INDIA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 210. INDIA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 211. INDONESIA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 212. INDONESIA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 213. INDONESIA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 214. INDONESIA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 215. INDONESIA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 216. INDONESIA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 217. INDONESIA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 218. INDONESIA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 219. INDONESIA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 220. INDONESIA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 221. INDONESIA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 222. INDONESIA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 223. INDONESIA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 224. INDONESIA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 225. JAPAN LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 226. JAPAN LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 227. JAPAN LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 228. JAPAN LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 229. JAPAN LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 230. JAPAN LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 231. JAPAN LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 232. JAPAN LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 233. JAPAN LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 234. JAPAN LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 235. JAPAN LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 236. JAPAN LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 237. JAPAN LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 238. JAPAN LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 239. MALAYSIA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 240. MALAYSIA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 241. MALAYSIA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 242. MALAYSIA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 243. MALAYSIA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 244. MALAYSIA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 245. MALAYSIA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 246. MALAYSIA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 247. MALAYSIA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 248. MALAYSIA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 249. MALAYSIA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 250. MALAYSIA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 251. MALAYSIA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 252. MALAYSIA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 253. PHILIPPINES LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 254. PHILIPPINES LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 255. PHILIPPINES LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 256. PHILIPPINES LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 257. PHILIPPINES LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 258. PHILIPPINES LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 259. PHILIPPINES LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 260. PHILIPPINES LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 261. PHILIPPINES LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 262. PHILIPPINES LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 263. PHILIPPINES LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 264. PHILIPPINES LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 265. PHILIPPINES LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 266. PHILIPPINES LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 267. SINGAPORE LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 268. SINGAPORE LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 269. SINGAPORE LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 270. SINGAPORE LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 271. SINGAPORE LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 272. SINGAPORE LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 273. SINGAPORE LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 274. SINGAPORE LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 275. SINGAPORE LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 276. SINGAPORE LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 277. SINGAPORE LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 278. SINGAPORE LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 279. SINGAPORE LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 280. SINGAPORE LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 281. SOUTH KOREA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 282. SOUTH KOREA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 283. SOUTH KOREA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 284. SOUTH KOREA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 285. SOUTH KOREA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 286. SOUTH KOREA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 287. SOUTH KOREA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 288. SOUTH KOREA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 289. SOUTH KOREA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 290. SOUTH KOREA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 291. SOUTH KOREA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 292. SOUTH KOREA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 293. SOUTH KOREA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 294. SOUTH KOREA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 295. TAIWAN LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 296. TAIWAN LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 297. TAIWAN LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 298. TAIWAN LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 299. TAIWAN LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 300. TAIWAN LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 301. TAIWAN LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 302. TAIWAN LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 303. TAIWAN LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 304. TAIWAN LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 305. TAIWAN LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 306. TAIWAN LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 307. TAIWAN LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 308. TAIWAN LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 309. THAILAND LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 310. THAILAND LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 311. THAILAND LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 312. THAILAND LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 313. THAILAND LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 314. THAILAND LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 315. THAILAND LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 316. THAILAND LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 317. THAILAND LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 318. THAILAND LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 319. THAILAND LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 320. THAILAND LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 321. THAILAND LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 322. THAILAND LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 323. VIETNAM LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 324. VIETNAM LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 325. VIETNAM LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 326. VIETNAM LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 327. VIETNAM LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 328. VIETNAM LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 329. VIETNAM LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 330. VIETNAM LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 331. VIETNAM LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 332. VIETNAM LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 333. VIETNAM LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 334. VIETNAM LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 335. VIETNAM LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 336. VIETNAM LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 337. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 338. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
• TABLE 339. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2030 (USD MILLION)
• TABLE 340. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2030 (USD MILLION)
• TABLE 341. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
• TABLE 342. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 343. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 344. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 345. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 346. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 347. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 348. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
• TABLE 349. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
• TABLE 350. EUROPE, MIDDLE EAST & AFRICA LIVE

The Livestock Medicine Market was valued at USD 19.56 billion in 2024 and is projected to grow to USD 20.56 billion in 2025, with a CAGR of 5.27%, reaching USD 26.63 billion by 2030.

The livestock medicine sector stands at a critical juncture-a dynamic environment where innovation, research, and technology converge to redefine treatment protocols and enhance productivity. In recent years, the industry has experienced significant changes driven by evolving consumer demands, regulatory pressures, and breakthrough scientific advancements. This report delves deep into the market, providing an extensive overview that merges current trends with actionable insights.

As the global population rises and the need for sustainable protein sources grows, livestock care becomes a key focus for pharmaceutical companies, veterinary professionals, and agricultural stakeholders. The scope of this comprehensive analysis includes a review of various factors affecting product development and application. It explores the convergence of scientific innovation with practical field applications, establishing an integrated narrative that is both informative and forward-looking.

In addition to presenting a detailed market overview, the report also highlights the transformative shifts in the sector. These changes have fostered a more scientific and data-driven approach to identifying growth opportunities, optimizing investments, and ultimately ensuring animal health management continuously evolves in pace with advancements in research and technology. Every discussion point is backed by robust data and grounded in real-world applications to empower decision-makers at every level.

Transformative Shifts in the Livestock Medicine Landscape

In the recent past, the landscape of livestock medicine has witnessed pivotal transformations resulting from technological integration, enhanced data analytics, and an increasing emphasis on precision veterinary care. The incorporation of advanced diagnostic tools and innovative treatment modalities has redefined traditional approaches, enabling veterinary professionals to adopt a proactive stance in mitigating disease outbreaks and optimizing animal productivity.

Recently, digital technologies have facilitated the collection and analysis of vast datasets, resulting in improved disease forecasting and optimized drug formulations. A notable shift has been the transition from conventional methodologies to a more holistic approach that factors in disease prevention and overall herd management. This evolving paradigm aligns with the global drive toward enhancing food security and achieving sustainable agricultural practices.

Furthermore, reforms in regulatory frameworks and evolving market dynamics are steering industry players to invest in research and development like never before. The adoption of cutting-edge solutions such as precision dosing and genetically tailored vaccines has not only improved treatment efficacy but also reduced the risk of drug resistance. These transformative shifts underscore the importance of innovative strategies and adaptive business models, ensuring that the sector remains agile and responsive amid ever-changing market conditions.

Key Segmentation Insights in the Evolving Market

A thorough understanding of market segmentation provides a multidimensional view of the livestock medicine landscape. These insights emerge from key segments defined by product type, disease type, animal type, formulation, route of administration, and end users. From the product type perspective, market research reveals that anti-inflammatory agents, antibiotics, antiparasitic agents, feed additives, hormones, and vaccines drive the industry. Delving deeper into each category, antibiotics are scrutinized based on cephalosporins, penicillins, and tetracyclines while antiparasitic agents are further analyzed across ectoparasiticides and endoparasiticides. Similarly, feed additives are dissected into prebiotics and probiotics, hormones are reviewed through the lens of growth and reproductive hormones, and vaccines are categorized into inactivated, live attenuated, and subunit vaccines.

Moreover, the segmentation based on disease type examines infectious diseases, metabolic diseases, nutritional deficiency diseases, parasitic diseases, and reproductive diseases. Each disease category presents unique challenges and growth opportunities that propel further innovation in treatment solutions. When considering animal type, the analysis spans aquaculture, cattle, goats, poultry, sheep, and swine, emphasizing how varied animal husbandry practices influence product demand and therapeutic approaches.

The segmentation by formulation categorizes offerings into capsules, gels, liquids, powders, and tablets, with a similar reflective partitioning observed in route of administration that spans inhalation, injectable, oral, and topical modalities. Notably, the injectable form is scrutinized meticulously across intramuscular and intravenous delivery, and the oral category distinguishes between liquids and tablet formulations, while the topical route is analyzed through creams and patches. Lastly, the segmentation based on end users focuses on the needs of livestock farmers, veterinary clinics, and veterinary hospitals. This detailed segmentation framework ensures a granular view, enabling stakeholders to identify specific market niches and target segments with precision and strategic clarity.

Based on Product Type, market is studied across Anti-inflammatory Agents, Antibiotics, Antiparasitic Agents, Feed Additives, Hormones, and Vaccines. The Antibiotics is further studied across Cephalosporins, Penicillins, and Tetracyclines. The Antiparasitic Agents is further studied across Ectoparasiticides and Endoparasiticides. The Feed Additives is further studied across Prebiotics and Probiotics. The Hormones is further studied across Growth Hormones and Reproductive Hormones. The Vaccines is further studied across Inactivated Vaccines, Live Attenuated Vaccines, and Subunit Vaccines.

Based on Disease Type, market is studied across Infectious Diseases, Metabolic Diseases, Nutritional Deficiency Diseases, Parasitic Diseases, and Reproductive Diseases.

Based on Animal Type, market is studied across Aquaculture, Cattle, Goats, Poultry, Sheep, and Swine.

Based on Formulation, market is studied across Capsules, Gels, Liquids, Powders, and Tablets.

Based on Route of Administration, market is studied across Inhalation, Injectable, Oral, and Topical. The Injectable is further studied across Intramuscular and Intravenous. The Oral is further studied across Liquids and Tablets. The Topical is further studied across Creams and Patches.

Based on End Users, market is studied across Livestock Farmers, Veterinary Clinics, and Veterinary Hospitals.

Key Regional Insights Across Major Global Markets

The geographical analysis of the livestock medicine market reveals a diverse and region-specific character that significantly influences market dynamics and strategic developments. Regions like the Americas have evolved into hubs characterized by advanced agricultural practices, robust regulatory frameworks, and a strong emphasis on modernization. The growth in this area is driven primarily by technological advancements and a highly competitive environment that encourages innovation and the adoption of new therapeutic solutions.

Turning the lens to the Europe, Middle East & Africa region, we observe a blend of mature markets with a progressive outlook in some areas and emerging growth opportunities in others. The interplay between stringent regulatory policies and region-specific health challenges creates a unique ecosystem in which stakeholders must constantly adapt to shifting market trends. Furthermore, evolving consumer awareness and mounting pressure for sustainable practices further contribute to reshaping the market landscape in these regions.

In the Asia-Pacific area, rapid economic growth, increasing investments in veterinary health, and a surge in demand for efficient, scalable therapeutic solutions have marked the region as a rising star in the global market. Innovation, supported by a surge in research initiatives and regional policy reforms, continues to tilt market trends in favor of integrated disease management strategies. This tri-regional analysis underscores the reality that successful market navigation requires an astute understanding of local dynamics combined with a global perspective on emerging challenges and opportunities.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Shaping the Industry Landscape

Prominent players have been instrumental in driving the evolution of the livestock medicine market by leveraging their expertise in research and development and forging strategic partnerships across international borders. Leaders such as Anicon Labor GmbH by SAN Group GmbH and AniCura Group by Mars Petcare have carved out significant market positions through consistent investment in cutting-edge technologies and robust research initiatives. Companies like Biogenesis Bago SA, Boehringer Ingelheim International GmbH, and Calier Laboratories S.A. further accentuate the competitive dynamics through their comprehensive product portfolios and innovative treatment modalities.

In addition, enterprises that have long been recognized as industry stalwarts, including Ceva Sante Animale, Dechra Pharmaceuticals PLC, and Elanco Animal Health Inc., continue to set high benchmarks in terms of product efficacy and market penetration. Noteworthy mentions also include HESTER BIOSCIENCES LIMITED and HIPRA S.A., which have emerged as key players driving the next wave of innovation in veterinary medicine. Other distinguished companies such as Indian Immunologicals Ltd., Koninklijke DSM N.V., Merck KGaA, and Neogen Corporation have significantly influenced market trends with their in-depth research and diversified therapeutic offerings.

Organizations like Norbrook Laboratories Ltd., Parnell Pharmaceuticals Holdings Ltd., and Phibro Animal Health Corporation have optimized their market strategies by targeting specific segmentation areas and investing in disruptive technologies. Vetoquinol S.A., Vetpharma Animal Health S.L., Virbac SA, and Zoetis Inc. also play a pivotal role in shaping market dynamics. Their collective efforts in improving drug formulations and expanding therapeutic categories are critical for addressing modern livestock health challenges effectively.

The report delves into recent significant developments in the Livestock Medicine Market, highlighting leading vendors and their innovative profiles. These include Anicon Labor GmbH by SAN Group GmbH, AniCura Group by Mars Petcare, Biogenesis Bago SA, Boehringer Ingelheim International GmbH, Calier Laboratories S.A., Ceva Sante Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health Inc., HESTER BIOSCIENCES LIMITED, HIPRA S.A., Indian Immunologicals Ltd., Koninklijke DSM N.V., Merck KGaA, Neogen Corporation, Norbrook Laboratories Ltd., Parnell Pharmaceuticals Holdings Ltd., Phibro Animal Health Corporation, Vetoquinol S.A., Vetpharma Animal Health S.L., Virbac SA, and Zoetis Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are advised to adopt a strategic framework that can effectively address the evolving complexities of the livestock medicine market. Initially, it is crucial to invest in robust research and development initiatives. Adopting a proactive stance by integrating advanced diagnostic technologies and digital monitoring systems can significantly enhance treatment outcomes. Stakeholders should focus on developing precision therapies that cater to distinct needs across various product and disease types.

Secondly, diversification into specialized segments is essential. A deep understanding of segmentation based on product type, disease type, animal type, formulation, route of administration, and end users provides an opportunity to tailor innovative products precisely aligned with market demands. Focusing on specific niches while also leveraging data-driven insights can streamline resource allocation and bolster competitive advantage.

Additionally, regional expansion strategies need careful consideration. Prioritizing regions such as the Americas for technological enhancements, the Europe, Middle East & Africa region for balancing mature dynamics with emerging trends, and the Asia-Pacific for leveraging booming growth potential can ensure a diversified revenue stream. Collaborations and strategic partnerships with local entities can significantly enhance market penetration and adaptability to regional regulatory frameworks.

Finally, decision-makers should keep a close watch on regulatory changes and market dynamics. Continuous monitoring of global trends and technological breakthroughs will not only mitigate risks but also enable the early adoption of breakthrough treatments and methodologies. Proactive risk management, together with targeted investment in innovation, provides the best pathway to staying ahead in a rapidly changing landscape.

Conclusion: Embracing the Future of Livestock Medicine

The evolving landscape of livestock medicine presents both significant challenges and unparalleled opportunities. In summing up, it is evident that technological integration, comprehensive segmentation analysis, and strategic regional insights are key drivers of the industry's future. The concerted efforts of leading companies, innovative research, and evolving market dynamics have all contributed to reshaping the market into a more resilient and adaptable environment.

As stakeholders continue to navigate this intricate landscape, the emphasis on precision therapies, data-driven decision making, and targeted geographic expansion becomes increasingly critical. The journey forward calls for a balanced approach that combines rigorous scientific inquiry with pragmatic business strategies to foster sustainable growth and robust market performance.

In essence, the livestock medicine market is on the brink of a transformative era. By embracing innovative practices and remaining alert to emerging trends, industry leaders can build a strong competitive advantage and drive significant value for both their organizations and the broader agricultural community.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased government regulations and initiatives to ensure animal welfare and minimize disease spread
    • 5.1.1.2. Growing awareness among livestock farmers about the benefits of preventive healthcare measures
    • 5.1.1.3. Rising prevalence of livestock diseases boosting investments in veterinary pharmaceuticals
  • 5.1.2. Restraints
    • 5.1.2.1. Limited research funding and innovation slowing down the development of next-generation livestock drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Expansion of antibiotic alternatives in livestock production in response to regulatory changes
    • 5.1.3.2. Collaboration with biotech firms to innovate groundbreaking vaccines for emerging livestock diseases
  • 5.1.4. Challenges
    • 5.1.4.1. Risks of disease outbreaks and biosecurity in the livestock industry
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type : Growing significance of antibiotics in preventing and managing bacterial infections among livestock populations
  • 5.2.2. End Users: Rising role of veterinary hospitals in the implementation of precision medicine for livestock
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Livestock Medicine Market, by Product Type

• 6.1. Introduction
• 6.2. Anti-inflammatory Agents
• 6.3. Antibiotics
  • 6.3.1. Cephalosporins
  • 6.3.2. Penicillins
  • 6.3.3. Tetracyclines
• 6.4. Antiparasitic Agents
  • 6.4.1. Ectoparasiticides
  • 6.4.2. Endoparasiticides
• 6.5. Feed Additives
  • 6.5.1. Prebiotics
  • 6.5.2. Probiotics
• 6.6. Hormones
  • 6.6.1. Growth Hormones
  • 6.6.2. Reproductive Hormones
• 6.7. Vaccines
  • 6.7.1. Inactivated Vaccines
  • 6.7.2. Live Attenuated Vaccines
  • 6.7.3. Subunit Vaccines

7. Livestock Medicine Market, by Disease Type

• 7.1. Introduction
• 7.2. Infectious Diseases
• 7.3. Metabolic Diseases
• 7.4. Nutritional Deficiency Diseases
• 7.5. Parasitic Diseases
• 7.6. Reproductive Diseases

8. Livestock Medicine Market, by Animal Type

• 8.1. Introduction
• 8.2. Aquaculture
• 8.3. Cattle
• 8.4. Goats
• 8.5. Poultry
• 8.6. Sheep
• 8.7. Swine

9. Livestock Medicine Market, by Formulation

• 9.1. Introduction
• 9.2. Capsules
• 9.3. Gels
• 9.4. Liquids
• 9.5. Powders
• 9.6. Tablets

10. Livestock Medicine Market, by Route of Administration

• 10.1. Introduction
• 10.2. Inhalation
• 10.3. Injectable
  • 10.3.1. Intramuscular
  • 10.3.2. Intravenous
• 10.4. Oral
  • 10.4.1. Liquids
  • 10.4.2. Tablets
• 10.5. Topical
  • 10.5.1. Creams
  • 10.5.2. Patches

11. Livestock Medicine Market, by End Users

• 11.1. Introduction
• 11.2. Livestock Farmers
• 11.3. Veterinary Clinics
• 11.4. Veterinary Hospitals

12. Americas Livestock Medicine Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Livestock Medicine Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Livestock Medicine Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Phibro Animal Health Corporation completes acquisition of Zoetis' medicated feed additive product portfolio
  • 15.3.2. Fischer MV partners with BAV to launch advanced vaccines in India
  • 15.3.3. Virbac's strategic acquisition of Sasaeah strengthens its position in Japan's livestock vaccine market
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Anicon Labor GmbH by SAN Group GmbH
• 2. AniCura Group by Mars Petcare
• 3. Biogenesis Bago SA
• 4. Boehringer Ingelheim International GmbH
• 5. Calier Laboratories S.A.
• 6. Ceva Sante Animale
• 7. Dechra Pharmaceuticals PLC
• 8. Elanco Animal Health Inc.
• 9. HESTER BIOSCIENCES LIMITED
• 10. HIPRA S.A.
• 11. Indian Immunologicals Ltd.
• 12. Koninklijke DSM N.V.
• 13. Merck KGaA
• 14. Neogen Corporation
• 15. Norbrook Laboratories Ltd.
• 16. Parnell Pharmaceuticals Holdings Ltd.
• 17. Phibro Animal Health Corporation
• 18. Vetoquinol S.A.
• 19. Vetpharma Animal Health S.L.
• 20. Virbac SA
• 21. Zoetis Inc.